<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02548754</url>
  </required_header>
  <id_info>
    <org_study_id>RSRCH135160</org_study_id>
    <secondary_id>15MCPRP25790001</secondary_id>
    <nct_id>NCT02548754</nct_id>
  </id_info>
  <brief_title>Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation</brief_title>
  <acronym>TREAT-AF</acronym>
  <official_title>TRanscutaneous Electrical vAgus Nerve sTimulation to Suppress Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is the most common cardiac arrhythmia. In previous experimental
      studies, the investigators found that low-level vagus nerve (VN) stimulation (LLVNS), at
      voltages substantially below that which slowed the sinus rate, significantly suppressed AF
      inducibility and decreased AF duration. The investigators subsequently developed a
      non-invasive neuromodulatory therapy, in which LLVNS was delivered to the auricular branch of
      the VN located at the tragus, the anterior protuberance of the outer canine ear (low level
      tragus stimulation; LLTS). The anti-arrhythmic effects of LLTS were similar to those of LLVNS
      delivered to the cervical VN trunk. More recently, in a proof-of-concept study in humans, the
      investigators showed that in patients with drug-refractory AF undergoing AF ablation, LLTS
      for just one hour significantly shortened the AF duration and decreased inflammatory
      cytokines.

      The overall objective of this proposal is to translate in ambulatory patients with paroxysmal
      AF the results of previous studies showing acute suppression of AF and inflammation in
      anesthetized canines as well as humans, in order to examine the long-term therapeutic effects
      of this approach. The investigators hypothesize that intermittent (1 hour daily) LLTS for 6
      months may result in long-term decrease of AF burden and suppression inflammatory cytokines
      in patients with paroxysmal AF. Patients will be randomized to either active or sham LLTS.
      LLTS will be delivered through a transcutaneous electrical nerve stimulation (TENS) device
      for 1 hour daily over a 6-month period. AF burden will be defined as the percent of time
      spent in AF over a 2-week period, assessed by noninvasive continuous ECG monitoring at
      baseline and at 6 months. In addition, blood samples will be collected from patients at
      baseline, and at 3 and 6 months, for cytokine measurement. These investigations will
      establish the first evidence of the long-term effects of LLTS on AF suppression in patients
      with paroxysmal AF and may provide the basis for a potential expansion of the therapeutic
      targets of this treatment modality beyond AF.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">March 2020</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial Fibrillation Burden</measure>
    <time_frame>6 months</time_frame>
    <description>Percent time spent in atrial fibrillation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Markers of Inflammation</measure>
    <time_frame>6 months</time_frame>
    <description>Serum levels of tumor necrosis factor-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Inflammation</measure>
    <time_frame>6 months</time_frame>
    <description>Serum levels of inteleukin 6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 1 hour of active low level tragus stimulation daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will receive 1 hour of sham low level tragus stimulation daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Parasym device</intervention_name>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients older than 21 year old

          2. Paroxysmal AF

        Exclusion Criteria:

          1. Left ventricular dysfunction (Left ventricular ejection fraction &lt;40%)

          2. Significant valvular disorder (i.e., prosthetic valve or hemodynamically relevant
             valvular diseases)

          3. Recent (&lt;6 months) stroke or myocardial infarction

          4. Severe heart failure (NYHA IV)

          5. Left atrial dilatation (&gt;55mm)

          6. Recurrent vaso-vagal syncopal episodes

          7. Unilateral or bilateral vagotomy

          8. Pregnancy or breast feeding

          9. Sick sinus syndrome, 2nd or 3rd degree AV block, bifascicular block or prolonged
             (PR&gt;300ms) 1st degree AV block.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stavros Stavrakis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2015</study_first_posted>
  <results_first_submitted>March 30, 2020</results_first_submitted>
  <results_first_submitted_qc>April 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2020</results_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>neuromodulation</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02548754/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active</title>
          <description>Patients will receive 1 hour of active low level tragus stimulation daily for 6 months
Parasym device</description>
        </group>
        <group group_id="P2">
          <title>Sham</title>
          <description>Patients will receive 1 hour of sham low level tragus stimulation daily for 6 months
Parasym device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active</title>
          <description>Patients will receive 1 hour of active low level tragus stimulation daily for 6 months
Parasym device</description>
        </group>
        <group group_id="B2">
          <title>Sham</title>
          <description>Patients will receive 1 hour of sham low level tragus stimulation daily for 6 months
Parasym device</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="15"/>
                    <measurement group_id="B2" value="68" spread="11"/>
                    <measurement group_id="B3" value="67" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AF burden</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" lower_limit="0.2" upper_limit="31"/>
                    <measurement group_id="B2" value="1" lower_limit="0" upper_limit="15"/>
                    <measurement group_id="B3" value="2.5" lower_limit="0.2" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Atrial Fibrillation Burden</title>
        <description>Percent time spent in atrial fibrillation</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Patients will receive 1 hour of active low level tragus stimulation daily for 6 months
Parasym device</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Patients will receive 1 hour of sham low level tragus stimulation daily for 6 months
Parasym device</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Fibrillation Burden</title>
          <description>Percent time spent in atrial fibrillation</description>
          <units>Percent time spent in atrial fibrillatio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="11"/>
                    <measurement group_id="O2" value="8.5" lower_limit="0" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Inflammation</title>
        <description>Serum levels of tumor necrosis factor-alpha</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Patients will receive 1 hour of active low level tragus stimulation daily for 6 months
Parasym device</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Patients will receive 1 hour of sham low level tragus stimulation daily for 6 months
Parasym device</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Inflammation</title>
          <description>Serum levels of tumor necrosis factor-alpha</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="3.9" upper_limit="8.3"/>
                    <measurement group_id="O2" value="5.4" lower_limit="4.4" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Inflammation</title>
        <description>Serum levels of inteleukin 6</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Patients will receive 1 hour of active low level tragus stimulation daily for 6 months
Parasym device</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Patients will receive 1 hour of sham low level tragus stimulation daily for 6 months
Parasym device</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Inflammation</title>
          <description>Serum levels of inteleukin 6</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.7" upper_limit="3.2"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>No device related adverse events reported</desc>
      <group_list>
        <group group_id="E1">
          <title>Active</title>
          <description>Patients will receive 1 hour of active low level tragus stimulation daily for 6 months
Parasym device</description>
        </group>
        <group group_id="E2">
          <title>Sham</title>
          <description>Patients will receive 1 hour of sham low level tragus stimulation daily for 6 months
Parasym device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stavros Stavrakis</name_or_title>
      <organization>University of Oklahoma Health Sciences Center</organization>
      <phone>4052714742</phone>
      <email>stavros-stavrakis@ouhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

